Prevention of hepatitis B virus reactivation under rituximab therapy

被引：10

作者：

Tsutsumi, Yutaka ^{[1
]}

Yamamoto, Yoshiya ^{[2
]}

Tanaka, Junji

Asaka, Masahiro ^{[3
]}

Imamura, Masahiro

Masauzi, Nobuo ^{[1
]}

机构：

[1] Hakodate Municipal Hosp, Dept Internal Med, Hakodate, Hokkaido 0418680, Japan

[2] Hakodate Municipal Hosp, Dept Gastroenterol, Hakodate, Hokkaido 0418680, Japan

[3] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol, Sapporo, Hokkaido, Japan

来源：

IMMUNOTHERAPY | 2009年 / 1卷 / 06期

关键词：

chemotherapy; hepatitis B virus; lamivudine; non-Hodgkin's lymphoma; reactivation; rituximab; ANTI-CD20; MONOCLONAL-ANTIBODY; NON-HODGKINS-LYMPHOMA; MANTLE-CELL LYMPHOMA; SURFACE-ANTIGEN; LOW-GRADE; PREEMPTIVE LAMIVUDINE; CANCER-PATIENTS; CYTOTOXIC CHEMOTHERAPY; PHASE-II; IMMUNOSUPPRESSIVE THERAPY;

D O I：

10.2217/IMT.09.59

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Rituximab is a useful drug for the treatment of B-cell non-Hodgkin's lymphoma, and its use has been extended to other diseases such as idiopathic thrombocytopenic purpura and chronic rheumatoid arthritis. One serious complication associated with rituximab use is reactivation of hepatitis B virus, and the search for methods to prevent this occurrence has resulted in a rapid accumulation of knowledge in recent years. In this review, we will discuss case studies from our group, as well as other groups, and outline current knowledge on the topic together with issues that remain to be resolved.

引用

页码：1053 / 1061

页数：9

共 109 条

[1] Prevention of hepatitis B flare-up during chemotherapy using lamivudine:: case report and review of the literature [J].

Al-Taie, OH ;

Mörk, H ;

Gassel, AM ;

Wilhelm, M ;

Weissbrich, B ;

Scheurlen, M .

ANNALS OF HEMATOLOGY, 1999, 78 (05) :247-249

[2] Occult hepatitis B virus infection [J].

Allain, JP .

TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2004, 11 (01) :18-25

[3] Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient [J].

Awerkiew, Sabine ;

Daeumer, Martin ;

Reiser, Marcel ;

Wend, Ulrike C. ;

Pfister, Herbert ;

Kaiser, Rolf ;

Willems, Wulf R. ;

Gerlich, Wolfram H. .

JOURNAL OF CLINICAL VIROLOGY, 2007, 38 (01) :83-86

[4]

Bermúdez A, 2000, HAEMATOLOGICA, V85, P894

[5]

BIRD GLA, 1989, Q J MED, V73, P895

[6]

CHEN AL, 1996, BLOOD, V87, P1627

[7] Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis-B surface antigen (HBSAG) seropositive cancer patients undergoing cytotoxic chemotherapy [J].

Cil, Timucin ;

Altintas, Abdullah ;

Pasa, Semir ;

Bayan, Kadim ;

Ozekinci, Tuncer ;

Isikdogan, Abdurrahman .

LEUKEMIA & LYMPHOMA, 2008, 49 (05) :939-947

[8] CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].

Coiffier, B ;

Lepage, E ;

Brière, J ;

Herbrecht, R ;

Tilly, H ;

Bouabdallah, R ;

Morel, P ;

Van den Neste, E ;

Salles, G ;

Gaulard, P ;

Reyes, F ;

Gisselbrecht, C .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242

[9]

Coiffier B, 1998, BLOOD, V92, P1927

[10] Hepatitis B virus reactivation in patients receiving chemotherapy for cancer treatment: Role of lamivudine prophylaxis [J].

Coiffier, Bertrand .

CANCER INVESTIGATION, 2006, 24 (05) :548-552

← 1 2 3 4 5 6 7 8 9 10 →